Selection and Identification of a DNA Aptamer for Multidrug-Resistant Acinetobacter baumannii Using an In-House Cell-SELEX Methodology
Carregando...
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
FRONTIERS MEDIA SA
Citação
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, v.12, article ID 818737, 9p, 2022
Resumo
Infections caused by multidrug-resistant A. baumannii are a worldwide health concern with high mortality rates. Rapid identification of this infectious agent is critical as it can easily spread with difficult or no options for treatment. In this context, the development of reliable and economically viable detection and therapeutic methodologies are still challenging. One of the promising solutions is the development of nucleic acid aptamers capable of interacting with bacteria. These aptamers can be used for specific recognition of infectious agents as well as for blocking their functions. Cell-SELEX technology currently allows the selection and identification of aptamers and is flexible enough to target molecules present in an entire bacterial cell without their prior knowledge. However, the aptamer technology is still facing many challenges, such as the complexity of the screening process. Here, we describe the selection and identification of a new aptamer A01, using an in-house whole-cell SELEX-based methodology, against multi-resistant Acinetobacter baumannii, with rapid execution and low cost. In addition, this protocol allowed the identification of the aptamer A01 with the whole A. baumannii cell as a target. The aptamer A01 demonstrated a binding preference to A. baumannii when compared to K. pneumoniae, C. albicans, and S. aureus in fluorescence assays. Although the time-kill assay did not show an effect on bacterial growth, the potential bactericidal or bacteriostatic cannot be totally discarded. The new categorized aptamer (A01) displayed a significant binding affinity to MDR A. baumannii.
Palavras-chave
aptamer, Acinetobacter banumannii, Cell-SELEX, protocol, multidrug resistance
Referências
- Afzal H., 2016, J MOL BIOMARK DIAGN, V07, P1, DOI [10.4172/2155-9929.1000309, DOI 10.4172/2155-9929.1000309]
- Bellaousov S, 2013, NUCLEIC ACIDS RES, V41, pW471, DOI 10.1093/nar/gkt290
- Boucher HW, 2009, CLIN INFECT DIS, V48, P1, DOI 10.1086/595011
- Carrillho CMDD, 2017, DIAGN MICR INFEC DIS, V87, P253, DOI 10.1016/j.diagmicrobio.2016.11.007
- Hamula CLA, 2015, J MOL EVOL, V81, P194, DOI 10.1007/s00239-015-9711-y
- Heiat M, 2017, BIOTECHNOL APPL BIOC, V64, P541, DOI 10.1002/bab.1507
- Kim LH, 2013, J KOREAN SOC APPL BI, V56, P165, DOI 10.1007/s13765-013-3019-7
- Lee B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14127-z
- Leite GC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151270
- Li HY, 2020, EMERG MICROBES INFEC, V9, P1671, DOI 10.1080/22221751.2020.1792352
- Pacheco ABF, 1997, J CLIN MICROBIOL, V35, P1521, DOI 10.1128/JCM.35.6.1521-1525.1997
- Petersen PJ, 2006, J ANTIMICROB CHEMOTH, V57, P573, DOI 10.1093/jac/dki477
- Rasoulinejad S, 2016, J BIOTECHNOL, V231, P46, DOI 10.1016/j.jbiotec.2016.05.024
- Sefah K, 2010, NAT PROTOC, V5, P1169, DOI 10.1038/nprot.2010.66
- Su CH, 2020, BIOSENS BIOELECTRON, V159, DOI 10.1016/j.bios.2020.112148
- Rozenblum GT, 2016, EXPERT OPIN DRUG DIS, V11, P127, DOI 10.1517/17460441.2016.1126244
- TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
- Ulrich H, 2004, CYTOM PART A, V59A, P220, DOI 10.1002/cyto.a.20056
- Zhou L, 2017, J FISH DIS, V40, P1831, DOI 10.1111/jfd.12656
- Zou XR, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01462
- Zou Y, 2018, J AGR FOOD CHEM, V66, P5677, DOI 10.1021/acs.jafc.8b01006